Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
nazartinib (EGF816)
i
Other names:
EGF816, EGF 816, EGF-816, NVS-816, NVS 816, NVS816
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Twitter
Trials
Company:
Novartis
Drug class:
EGFR inhibitor
Related drugs:
‹
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (39)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
furmonertinib (11)
lazertinib (9)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
SH-1028 (1)
HLX07 (1)
KD019 (1)
AZD3759 (1)
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (39)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
furmonertinib (11)
lazertinib (9)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
SH-1028 (1)
HLX07 (1)
KD019 (1)
AZD3759 (1)
›
Associations
(4)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGFR T790M + MET positive
Non Small Cell Lung Cancer
EGFR T790M + MET positive
Non Small Cell Lung Cancer
capmatinib + EGF816
Sensitive: C3 – Early Trials
capmatinib + EGF816
Sensitive
:
C3
capmatinib + EGF816
Sensitive: C3 – Early Trials
capmatinib + EGF816
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login